Leveraging Technology to Cut Through the REMS Confusion
The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.
You may also like:
The problem of alert fatigue — the negative or overwhelmed reaction of clinicians to receiving too many intrusive or irrelevant notifications from electronic health record (EHR) systems — continues to vex clinicians, s...
Over the last several decades, clinical decision support solutions have demonstrated success in helping improve quality of care in the American healthcare system. But the need to “broaden that impact” has led professionals to ...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!